These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8066063)

  • 41. Successful treatment of myelodysplastic syndrome-associated anaemia with rhGM-CSF.
    Hansen PB; Pri TK; Hippe E
    Presse Med; 1994 Jun; 23(22):1042. PubMed ID: 7971812
    [No Abstract]   [Full Text] [Related]  

  • 42. [Advances in the research of clinical use of recombinant human granulocyte colony-stimulating factors].
    Jiang FG; Geng JP; Yang CL
    Zhonghua Nei Ke Za Zhi; 1991 Nov; 30(11):723-5. PubMed ID: 1726145
    [No Abstract]   [Full Text] [Related]  

  • 43. Methimazole-induced severe aplastic anemia: unsuccessful treatment with recombinant human granulocyte-monocyte colony-stimulating factor.
    Escobar-Morreale HF; Bravo P; García-Robles R; García-Laraña J; de la Calle H; Sancho JM
    Thyroid; 1997 Feb; 7(1):67-70. PubMed ID: 9086574
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C; Zahner J; Sayer HG
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased levels of multiple forms of dihydrofolate reductase in peripheral blood leucocytes of cancer patients receiving haematopoietic colony-stimulating factors: interim analysis.
    Iqbal MP; Burney IA; Sultana F; Mehboobali N; Siddiqui T
    Exp Mol Med; 2000 Jun; 32(2):84-7. PubMed ID: 10926120
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
    Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
    Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GM-CSF in Hodgkin disease.
    Bagley CM
    Ann Intern Med; 1992 Jun; 116(12 Pt 1):1033; author reply 1033-4. PubMed ID: 1586096
    [No Abstract]   [Full Text] [Related]  

  • 48. c-kit ligand augments granulocyte-macrophage colony growth from patients with 5q- syndrome.
    Rosenfeld CS; Nemunaitis J; Sherer CR; Zeigler ZR; Shadduck RK
    Stem Cells; 1993 Nov; 11(6):562-7. PubMed ID: 7509225
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of granulocyte colony stimulating factor on the specific macrophage marker neopterin in cancer patients.
    Lissoni P; Barni S; Grassi MG; Tancini G
    Int J Biol Markers; 1995; 10(1):61-2. PubMed ID: 7629430
    [No Abstract]   [Full Text] [Related]  

  • 50. Is granulocyte-macrophage colony-stimulating factor (GM-CSF) safe in myelodysplastic syndromes?
    Mittelman M; Floru S; Pick AI
    Haematologia (Budap); 1994; 26(2):111-5. PubMed ID: 7890261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Growth of human hematopoietic colonies from patients with myelodysplastic syndromes in response to recombinant human granulocyte-macrophage colony-stimulating factor.
    Carlo-Stella C; Cazzola M; Bergamaschi G; Bernasconi P; Dezza L; Invernizzi R; Pedrazzoli P
    Leukemia; 1989 May; 3(5):363-6. PubMed ID: 2654496
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Urinary neopterin levels in hematologic malignancies.
    Santelli G; Marfella A; Abate G; Comella P; Nitsch F; Perna M
    Tumori; 1986 Apr; 72(2):139-43. PubMed ID: 3705186
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Colony-stimulating factors: use in the pediatric population (Part I).
    Phillips E; Restino MS
    J Pediatr Health Care; 1994; 8(2):82-6. PubMed ID: 8158493
    [No Abstract]   [Full Text] [Related]  

  • 54. Overuse of granulocyte colony-stimulating factor in acute myeloid leukemia, aplastic anemia and myelodysplastic syndrome.
    Shinohara K
    Intern Med; 2000 Jan; 39(1):82. PubMed ID: 10674858
    [No Abstract]   [Full Text] [Related]  

  • 55. Clearance of unremitting psoriasis after treatment with granulocyte-macrophage colony-stimulating factor.
    Raychaudhuri SP; Fiore MM
    J Am Acad Dermatol; 1992 Sep; 27(3):451-2. PubMed ID: 1401283
    [No Abstract]   [Full Text] [Related]  

  • 56. Successful treatment of gold-induced aplastic anaemia with granulocyte macrophage colony stimulating factor.
    Chasen MR; Sarembock B; Meyers OL
    Br J Rheumatol; 1992 Jun; 31(6):428-9. PubMed ID: 1596710
    [No Abstract]   [Full Text] [Related]  

  • 57. Neopterin: biopterin ratios in Down's syndrome.
    Cattell RJ; Hamon CG; Corbett JA; Lejeune J; Blair JA
    J Neurol Neurosurg Psychiatry; 1989 Aug; 52(8):1015-6. PubMed ID: 2529354
    [No Abstract]   [Full Text] [Related]  

  • 58. Hypoalbuminaemia after prolonged treatment with recombinant granulocyte macrophage colony stimulating factor.
    Kaczmarski RS; Mufti GJ
    BMJ; 1990 Dec; 301(6764):1312-3. PubMed ID: 2271856
    [No Abstract]   [Full Text] [Related]  

  • 59. High urinary neopterin levels in Familial Mediterranean Fever.
    Simsek H; Kadayifci A; Altindag ZZ; Sahin G
    Clin Exp Rheumatol; 1996; 14(2):224-5. PubMed ID: 8737737
    [No Abstract]   [Full Text] [Related]  

  • 60. Activation of cellular immune responses in melioidosis patients as assessed by urinary neopterin.
    Brown AE; Dance DA; Chaowagul W; Webster HK; White NJ
    Trans R Soc Trop Med Hyg; 1990; 84(4):583-4. PubMed ID: 2091357
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.